Literature DB >> 2117386

Effects of glyburide on carbohydrate metabolism and insulin action in the liver.

J F Caro1.   

Abstract

Increased hepatic glucose production is responsible for fasting hyperglycemia in type II diabetes. Insulin resistance is the key in this process because of the inability of insulin to suppress hepatic glucose production, thereby allowing an unopposed glucagon effect. Glyburide, one of the second-generation sulfonylureas, decreases glucose production and enhances insulin action in the liver. Available data suggest that glyburide: (1) enhances glycogen synthesis in the liver by increasing glycogen synthase; (2) inhibits glycogenolysis by decreasing phosphorylase alpha activity; and (3) decreases gluconeogenesis and stimulates glycolysis by decreasing A-kinase activity, which results in increased fructose 2,6-bisphosphate, one of the key regulators of carbohydrate metabolism in the liver. The effect of glyburide on the insulin-signaling mechanism(s) is distal to the insulin binding site of the alpha-subunit of the insulin receptor and the tyrosine kinase activation site of the beta-subunit.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2117386     DOI: 10.1016/0002-9343(90)90332-8

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  7 in total

1.  Specific inhibition of the plasmodial surface anion channel by dantrolene.

Authors:  Godfrey Lisk; Myungsa Kang; Jamieson V Cohn; Sanjay A Desai
Journal:  Eukaryot Cell       Date:  2006-09-01

2.  Tolbutamide causes open channel blockade of cystic fibrosis transmembrane conductance regulator Cl- channels.

Authors:  C J Venglarik; B D Schultz; A D DeRoos; A K Singh; R J Bridges
Journal:  Biophys J       Date:  1996-06       Impact factor: 4.033

3.  Glibenclamide treatment blocks metabolic dysfunctions and improves vagal activity in monosodium glutamate-obese male rats.

Authors:  Claudinéia C S Franco; Kelly V Prates; Carina Previate; Ana M P Moraes; Camila C I Matiusso; Rosiane A Miranda; Júlio C de Oliveira; Laize P Tófolo; Isabela P Martins; Luiz F Barella; Tatiane A Ribeiro; Ananda Malta; Audrei Pavanello; Flávio A Francisco; Rodrigo M Gomes; Vander S Alves; Veridiana M Moreira; Késia P Rigo; Douglas L Almeida; Juliane R de Sant Anna; Marialba A A C Prado; Paulo C F Mathias
Journal:  Endocrine       Date:  2017-02-23       Impact factor: 3.633

4.  Effects of P1060 and aprikalim on whole-cell currents in rat portal vein; inhibition by glibenclamide and phentolamine.

Authors:  T Ibbotson; G Edwards; T Noack; A H Weston
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

5.  Antagonism of levcromakalim by imidazoline- and guanidine-derivatives in rat portal vein: involvement of the delayed rectifier.

Authors:  T Ibbotson; G Edwards; A H Weston
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

Review 6.  SX-fraction: Promise for novel treatment of type 2 diabetes.

Authors:  Sensuke Konno
Journal:  World J Diabetes       Date:  2020-12-15

7.  Possible hypoglycemic action of SX-fraction targeting insulin signal transduction pathway.

Authors:  Sensuke Konno; Bobby Alexander; John Zade; Muhammad Choudhury
Journal:  Int J Gen Med       Date:  2013-03-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.